Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Linagliptin recommended for approval in the treatment of type 2 diabetes in Europe

June 24, 2011 By Bio-Medicine.Org

RIDGEFIELD, Conn. and INDIANAPOLIS, June 24, 2011 /PRNewswire/
— Boehringer Ingelheim and Eli Lilly and Company (NYSE:
LLY
) today received a positive opinion from the European
Medicines Agency’s (EMA) medicinal committee recommending approval
of linagliptin, 5 mg, film-coated tablets (to be marketed under the
trade name Trajenta® in Europe) for the treatment of adults
with type 2 diabetes. If adopted by the European Commission,
linagliptin will be the only DPP-4 inhibitor approved at one dosage
strength for patients with type 2 diabetes in Europe.
 Linagliptin, 5 mg, is marketed under the trade name
Tradjenta™ (linagliptin) tablets in the U.S. and was approved
by the U.S. Food and Drug Administration (FDA) in May 2011 to be
used along with diet and exercise to lower blood sugar in adults
with type 2 diabetes.  Linagliptin should not be used in
patients with type 1 diabetes or for the treatment of diabetic
ketoacidosis (increased ketones in the blood or urine). It has not
been studied in combination with insulin.

The Committee for Medicinal Products for Human Use (CHMP) has
recommended the approval of linagliptin as monotherapy in patients
inadequately controlled by diet and exercise alone and for whom
metformin is inappropriate due to intolerance, or contraindicated
due to renal impairment. Linagliptin is also recommended for
approval in combination with metformin and metformin plus
sulfonylurea. Data showed linagliptin plus metformin reduced
hemoglobin A1C (HbA1C or A1C) levels by a mean of 0.6 to 0.7
percent (compared to placebo). A1C is measured in people with
diabetes to provide an index of blood glucose control for the
previous two to three months. It is used as a marker to determine
the efficacy of glucose-lowering therapies.

“This will be an important step forward in the management of
type 2 diabetes in Europe,” said Prof. Anthony Ba

‘/>”/>

SOURCE

Related Articles Read More >

Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age
A Medtronic HVAD pump opened up to show the inner workings
Medtronic investigates HVAD pump welds after patient deaths
Galien Foundation 2022 nominees
18 of the world’s most innovative medical technologies

DeviceTalks Weekly.

May 13, 2022
Our Pre-Post-DeviceTalks Boston episode, also MedtronicTalks replay with Gastro CMO Austin Chiang
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech